Methimazole vs PTU: Which Antithyroid Drug Is Right for You?

What Are Methimazole and PTU, and How Do They Work?

Methimazole (brand names Tapazole and Northyx) and propylthiouracil (PTU) are both thionamide drugs that block thyroid hormone synthesis by inhibiting thyroid peroxidase, the enzyme that incorporates iodine into thyroglobulin. PTU has a second mechanism: at doses above 450 mg/day it also partially blocks peripheral conversion of T4 to the more active T3 by inhibiting deiodinase enzymes. This extra action makes PTU useful in thyroid storm, where rapid T3 reduction matters. Methimazole does not share that peripheral effect.

Both drugs are taken by mouth and absorbed quickly, but their pharmacokinetics differ in ways that shape everyday prescribing. Methimazole has a plasma half-life of 6-8 hours and a duration of thyroid action well beyond that, allowing reliable once-daily dosing [1]. PTU has a half-life of only 1-2 hours, which forces dosing every 6-8 hours and creates greater room for missed-dose failures [1]. The American Thyroid Association (ATA) 2016 guidelines state directly: "We recommend methimazole be used in essentially every patient who chooses antithyroid drug therapy, except during the first trimester of pregnancy when PTU is preferred, in the treatment of thyroid storm, and in patients with minor reactions to methimazole who refuse radioactive iodine therapy or surgery." [2]

A 2019 meta-analysis in Thyroid (N=1,334 patients across 10 randomized trials) confirmed that methimazole and PTU produce statistically equivalent rates of euthyroidism at 4-8 weeks, but methimazole achieved biochemical control roughly one week sooner on average [3].

Head-to-Head Safety Comparison

The most clinically significant difference between the two drugs is their hepatotoxicity profiles. Methimazole can cause a cholestatic pattern of liver injury that is generally reversible with drug discontinuation. PTU carries risk of severe fulminant hepatic necrosis. A 2010 FDA safety review of post-marketing data identified 32 cases of serious PTU-associated liver failure, including 13 deaths and 5 liver transplants, prompting a black-box warning [4]. No comparable signal exists for methimazole-related liver failure.

Both drugs share several class-wide side effects.

Agranulocytosis occurs in roughly 0.2-0.5% of patients on either drug [5]. It typically presents as abrupt high fever and sore throat, usually within the first 90 days of therapy. Patients must be counseled to stop the drug immediately and seek a white blood cell count if those symptoms appear. Routine monitoring of white blood cell counts is not recommended by ATA guidelines because agranulocytosis develops abruptly between checks, but a baseline complete blood count is reasonable [2].

Minor reactions (rash, urticaria, arthralgias, mild transaminase elevation) occur in 5-15% of patients [5]. Up to 50% of patients with a minor reaction to one thionamide will cross-react to the other, so switching drugs for a minor reaction is not always safe and should prompt a reconsideration of radioactive iodine or surgery [2].

ANCA-associated vasculitis is a rare but serious complication linked predominantly to PTU, not methimazole. A 2009 study in Thyroid reported ANCA positivity in up to 64% of long-term PTU users vs. approximately 5% on methimazole, with clinical vasculitis in a smaller but significant subset [6]. This further restricts PTU's role to short-term or pregnancy-specific use.

Dosing Protocols in Clinical Practice

Starting doses depend on the severity of hyperthyroidism, assessed by free T4 level, T3 level, and clinical picture.

For methimazole, the ATA recommends:

• Mild hyperthyroidism (free T4 less than 1.5 times upper limit of normal): 5-10 mg once daily
• Moderate hyperthyroidism (free T4 1.5-2 times upper limit): 10-20 mg once daily
• Severe hyperthyroidism (free T4 greater than 2-3 times upper limit): 30-40 mg once daily [2]

Thyroid function tests (free T4 and total T3) are rechecked at 4-6 weeks and the dose titrated downward as levels normalize. TSH often remains suppressed for months after T4/T3 normalize and should not be the primary titration target early in treatment [2].

For PTU, a standard starting dose is 100-150 mg every 8 hours (300-450 mg/day total), with severe cases or thyroid storm requiring up to 600-1 to 000 mg/day [7]. Once euthyroid, many clinicians transition patients to methimazole to reduce the hepatotoxicity burden and simplify dosing.

Liver function tests (ALT, AST) should be checked at baseline and periodically during PTU therapy [4]. The FDA label now requires that prescribers inform PTU patients about the liver failure risk at the time of prescribing.

PTU in Pregnancy: The One Setting Where It Leads

The choice between antithyroid drugs reverses during the first trimester of pregnancy. Methimazole is associated with a rare embryopathy syndrome that includes choanal atresia, esophageal atresia, aplasia cutis, and a characteristic facial pattern. The risk is small, estimated at roughly 2-4 per 1,000 exposed pregnancies, but the consequences are severe [8]. PTU does not carry the same teratogenic profile and is the drug of choice from conception through week 12-14 [2].

After the first trimester, the teratogenic window for methimazole closes, and many guidelines recommend switching back to methimazole to protect the mother from PTU-related liver injury [2]. Fetal exposure to both drugs can suppress fetal thyroid function, so the goal is always the lowest effective dose that keeps the mother's free T4 at or just above the upper limit of the trimester-specific reference range [8].

A 2013 Danish cohort study (N=564 pregnant women with Graves disease) published in the Journal of Clinical Endocrinology and Metabolism found that infants exposed to methimazole in the first trimester had a 2.1-fold higher risk of birth defects compared with PTU-exposed infants (6.1% vs. 2.3%, P<0.01) [9]. That single dataset has strongly shaped current prescribing practice for gestational hyperthyroidism.

Breast-feeding: both drugs pass into breast milk. Methimazole at doses up to 20-30 mg/day and PTU at doses up to 300 mg/day are considered compatible with breast-feeding per ATA guidance, provided the infant's thyroid function is monitored [2].

Radioactive Iodine vs. Thyroidectomy: When Drug Therapy Is Not Enough

Antithyroid drug therapy produces remission in only 40-60% of Graves disease patients after 12-18 months [2]. For those who relapse, or for patients with toxic nodular goiter (where remission on drugs is rare), definitive therapy is needed.

Radioactive iodine (RAI, I-131) ablates thyroid tissue over 6-18 months. A single dose achieves euthyroidism or hypothyroidism in approximately 80-90% of Graves disease patients [10]. Most patients will eventually require lifelong levothyroxine after RAI, which is considered a success rather than a complication. RAI is contraindicated in pregnancy and active moderate-to-severe thyroid eye disease (it can worsen orbitopathy). Pre-treatment with methimazole is stopped 3-5 days before RAI to allow adequate iodine uptake; PTU may blunt the radiation effect more than methimazole does and should ideally be stopped 1-2 weeks before the dose [2].

Thyroidectomy (total or near-total) cures hyperthyroidism in greater than 95% of patients when performed by a high-volume thyroid surgeon (defined as more than 25 thyroidectomies per year) [11]. It is preferred when RAI is contraindicated, when a large goiter causes compressive symptoms, when suspicious thyroid nodules coexist, or when the patient wants the fastest path to a definitive outcome. Risks include permanent hypoparathyroidism (approximately 1-2% with experienced surgeons) and recurrent laryngeal nerve injury (less than 1%) [11]. Patients must be rendered euthyroid with antithyroid drugs before surgery to prevent thyroid storm; beta-blockers and potassium iodide (Lugol solution) are added in the two weeks before the operation to reduce gland vascularity [2].

The table below outlines the HealthRX clinical decision framework for choosing among the three treatment options:

| Factor | Prefer RAI | Prefer Surgery | Continue Antithyroid Drug | |---|---|---|---| | Graves disease, no eye disease | Yes | If large goiter | If patient desires remission attempt | | Active moderate-severe TED | No | Yes | Bridge only | | Toxic multinodular goiter | Yes | Yes | Rarely curative | | Pregnancy | No | Second trimester only if urgent | First-line (PTU then switch) | | Suspicious nodule | No | Yes | Bridge only | | Age <18 | Rarely | Preferred if drug fails | First-line |

Synthroid vs. Generic Levothyroxine (and Tirosint)

Most patients with Graves disease who receive RAI or thyroidectomy, and all patients with hypothyroidism, need thyroid hormone replacement. Levothyroxine (synthetic T4) is the standard of care. Three formulations dominate the U.S. market.

Synthroid is a brand-name levothyroxine tablet made by AbbVie. Generic levothyroxine tablets are bioequivalent by FDA standards, defined as area-under-the-curve and peak concentration within 80-125% of the reference product. A 2020 randomized crossover trial (N=48) in Thyroid found no statistically significant difference in TSH, free T4, or free T3 between Synthroid and generic levothyroxine at equivalent labeled doses [12]. Cost matters: generic levothyroxine often runs under $10 per month vs. $40-80 for branded Synthroid without insurance.

Tirosint is a liquid-gel capsule formulation of levothyroxine containing only gelatin, glycerin, water, and levothyroxine, with no dyes, fillers, or acacia. It is FDA-approved and indicated for patients who have absorption problems (bariatric surgery patients, those with severe atrophic gastritis, or those on proton pump inhibitors). A pharmacokinetic study (N=29) showed Tirosint produces 22% higher peak T4 absorption compared with conventional tablets, which can matter for patients who have been chronically under-replaced on standard tablets [13]. Tirosint carries a substantially higher cost than generic levothyroxine, often $80-150 per month.

Armour Thyroid (desiccated thyroid extract, DTE) contains both T4 and T3 derived from porcine thyroid glands. The T4:T3 ratio in porcine thyroid (approximately 4:1) differs from endogenous human thyroid secretion (approximately 20:1), meaning DTE delivers a supraphysiologic T3 load relative to T4. A randomized crossover trial published in JCEM (N=70) found that 48.6% of patients preferred DTE over levothyroxine for mood and overall well-being, though thyroid function tests (TSH) were not significantly different between the two conditions [14]. The Endocrine Society's 2012 position statement notes insufficient evidence to recommend DTE over levothyroxine as routine therapy, citing the supraphysiologic T3 peaks as a concern in patients with cardiovascular disease [15].

Monitoring and Long-Term Management

Patients on antithyroid drugs for Graves disease typically continue therapy for 12-18 months before a trial off medication. Predictors of remission include small goiter size, mild initial TSH-receptor antibody (TRAb) elevation, and normalization of TRAb during therapy [2]. A 2019 prospective study in European Thyroid Journal (N=317) showed that TRAb negativity at 12 months predicted remission in 72% of patients vs. 22% in those still TRAb-positive [16]. Measuring TRAb before stopping therapy is strongly recommended.

After stopping antithyroid drugs, TSH and free T4 should be checked at 4-6 weeks, then every 3 months for one year, and annually thereafter if the patient remains euthyroid [2]. Approximately 50% of patients who achieve remission will relapse within 5 years [2]. A second course of antithyroid drugs is reasonable, but relapse rates after a second course are similar to the first, and definitive therapy should be discussed more forcefully at that point.

For patients on levothyroxine replacement (post-RAI, post-thyroidectomy, or primary hypothyroidism), TSH should be checked 6-8 weeks after any dose change and annually once stable [17]. TSH target ranges vary by indication: 0.5-2.5 mIU/L for most adults, 0.1-0.5 mIU/L for high-risk thyroid cancer patients on suppression therapy, and 0.5-1.5 mIU/L for pregnant women in the first trimester [17]. The ATA 2019 hypothyroidism guidelines recommend maintaining stable formulation (brand or generic) to avoid TSH fluctuations that arise from switching between formulations with slightly different bioavailability profiles [17].

Calcium carbonate, iron supplements, proton pump inhibitors, and certain bile-acid sequestrants all reduce levothyroxine absorption. Patients should take levothyroxine on an empty stomach, 30-60 minutes before food, and at least 4 hours away from these agents [17].